Hatfield, PA, United States of America

Shigeko Yamazaki

This inventor holds 3 USPTO granted patents. Top assignee: Merck + Co., Inc.. Active years: 1991-1999.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Shigeko Yamazaki. Retrieved from https://idiyas.com/inventor/shigeko-yamazaki

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 1.3

ph-index = 1

Forward Citations = 14(Granted Patents)


Location History:

  • Hatfield, PA (US) (1991)
  • Edison, NJ (US) (1999)

Company Filing History:


Years Active: 1991-1999

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Shigeko Yamazaki: Innovator in Biochemical Processes

Introduction

Shigeko Yamazaki is a notable inventor based in Hatfield, PA (US). She has made significant contributions to the field of biochemistry, particularly in the development of processes for synthesizing pharmaceutical compounds. With a total of 3 patents to her name, her work has had a meaningful impact on the industry.

Latest Patents

One of her latest patents is titled "Process for bioreduction of bisaryl ketone to bisaryl alcohol." This invention focuses on an improved method for creating PDE IV inhibitors. Specifically, it describes a process for making and purifying a chiral bisaryl alcohol, which is an essential intermediate for the preparation of PDE IV inhibitors like CDP 840. The process utilizes a microorganism's ability to reduce a pro-chiral bisaryl ketone to the chiral bisaryl alcohol, which can then be isolated through various purification methods. This innovation enhances the production of each enantiomer of the bisaryl alcohol at elevated optical purity.

Another significant patent is the "Method of purifying recombinant pres-1/S-2/S/S hepatitis B antigen." This invention outlines a rapid purification method for recombinant hepatitis B antigen that is bound to yeast membranes in yeast expression systems. The method involves using agents that release undesired proteins, followed by agents that specifically release the recombinant hepatitis B antigen.

Career Highlights

Shigeko Yamazaki is currently employed at Merck & Co., Inc., where she continues to advance her research in biochemistry and pharmaceuticals. Her work has been instrumental in developing innovative solutions that address complex challenges in drug synthesis and purification.

Collaborations

Throughout her career, Shigeko has collaborated with esteemed colleagues, including Hywyn Ro Churchill and Woo-Baeg Choi. These partnerships have fostered a collaborative environment that enhances the quality and impact of their research.

Conclusion

Shigeko Yamazaki's contributions to the field of biochemistry exemplify the importance of innovation in pharmaceutical development. Her patents reflect a commitment to advancing scientific knowledge and improving drug synthesis processes. Her work continues to inspire future generations of inventors and researchers.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…